期刊文献+

糖尿病肾病患者血 尿血管紧张素原的测定及意义 被引量:2

The clinical effects of plasma and urinary angiotensinogen on type 2 diabetic nephropathy
下载PDF
导出
摘要 目的探讨血管紧张素原(AGT)对2型糖尿病肾病(DN)的影响。方法将46例DN患者分为早期糖尿病肾病组(EDN组)20例、临床糖尿病肾病组(CDN组)26例,另有32例为正常对照组(NC组),采用ELISA法检测各组血清和尿中的AGT水平。结果 1)EDN组、CDN组较NC组血清AGT水平明显升高,有显著性差异(F值:54.327,P<0.05),而EDN组、CDN组之间无显著性差异;与EDN组比较,CDN组尿AGT水平高,NC组低,各组间有显著性差异(F值:207.113,P<0.05)。2)2型糖尿病肾病患者的血清AGT水平与尿AGT水平无相关性。结论尿血管紧张素原可能是反映2型糖尿病肾病肾功能损害程度的指标。 Objective To study the effect of angiotensinogen (AGT)on type 2 diabetic nephropathy (DN) ~ Methods 46 cases patients of DN were divided into 20 cases of early phase DN(EDN), 26 cases of clinic phase DN(CDN) ,another 32 cases for normal control (NC), whose plasma and urinary AGT was measured by ELISA. Results 1)Plasma AGT levels in the EDN group and CDN group was significantly higher than the NC group(F..54. 327,P〈0.05). Urinary AGT levels in the EDN group was significantly higher than the NC group, and CDN group was significantly higher than the EDN group(F.. 207.113, P〈0.05). (2)Plasma AGT levels was no significant corre- lated with urinary AGT levels. Conclusion Urinary AGT can be an item to show the damage degree of type 2 DN.
出处 《济宁医学院学报》 2013年第2期115-117,共3页 Journal of Jining Medical University
关键词 糖尿病肾病 血管紧张素原 Diabetic Nephropathy AGT
  • 相关文献

参考文献7

  • 1Yiannikouris F, Karounos M, Charnigo R, et al. Adipocyte-.specific deficiency of angiotensinogen decreases plasma an-giotensinogen concentration and systolic blood pressure inmice[J]. Am J Physiol Requt Inteqr Comp Physiol,2012 ,302(2):R244-R251. 被引量:1
  • 2Wu C,Lu H,Cassis LA,et al. Molecular and Pathophysiolog-ical Features of Angiotensinogen: A Mini Review[J]. N Am JMed Sci (Boston) ,2011,4(4) : 183-190. 被引量:1
  • 3Urushihara M,Kondo S,Kagami S, et al. Urinary angio-tensinogen accurately reflects intrarenal renin-angiotensinsystem activity[J]. Am J Nephrol,2010,31 (4) :318-325. 被引量:1
  • 4Li XC·Navar LG, Shao Y,et al. Genetic deletion of ATI a re-ceptors attenuates intracellular accumulation of ANG II inthe kidney of ATI a receptor-deficient mice[J]. Am J PhysiolRenat Physiol,2007,293(2) :F586-F593. 被引量:1
  • 5邹健,田丰,孙圣燕,宋海峰.肾素-血管紧张素系统与糖尿病肾病[J].人民军医,2012,55(1):68-70. 被引量:6
  • 6Kobori H, Nishiyama A. Effeets of tempol on renal angio-tensinogen production in Dahl salt-sensitive rats[J]. BiochemBiophys Res Commun,2004,315(30) :746-750. 被引量:1
  • 7Kim S,Iwao H. Molecular and cellular mechanisms of angio-tensin II -mediated cardiovascular and renal diseases [J].Pharmacol Rev,2000,52(1) : 11-34. 被引量:1

二级参考文献14

  • 1Unger T. The ngiotensin type 2 receptor: Variations on enigmatic themes[J]. Hypertension, 1997,17(12 Pt 2):1775-1786. 被引量:1
  • 2MarsoS,SternD,著.张代富,主译.糖尿病与心血管疾病[M].北京:人民卫生出版社,2006. 被引量:1
  • 3Pippin J, Bain SC, Barnett AH,et al. Rationale and design of diabetics exposed to telmisartan and enalapril (DETAIL) study[J]. J Diabetes Complications, 2002,16(3) : 195-200. 被引量:1
  • 4Brenner BM,Cooper ME,de Zeeuw D,et al. The losartan renal pro tection study-rationale, study design and baseline eharaetefistiesof RENAAL(reduction of endpoints in NIDDM with the angiotensin II antagonist losanan) [J]. J Renin Angiotensin Aldosterone Syst, 2000, 1(4) :328-335. 被引量:1
  • 5Lewis EJ, Hunsicker LG, Clarke WR,et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in. patients with ne- phropathy due to type 2 diabetes[J]. New Engl J Med, 2001,345(12):851-860. 被引量:1
  • 6Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes[J]. New Engl J Meal,2001,345(12) :861 869. 被引量:1
  • 7Agntwal R, Siva S, Dunn SR, et al. Add-on Angiotensin Ⅱ Receptor blockadee lower surinary transforming growth factor-beta levels [J]. Am J Kidney Dis,2002,39(3) :486-492. 被引量:1
  • 8Ruggenenti P, bassi A, Ilieva AP, et al. Preventing rnicroalbuminuria in type 2 diabetes[J]. New Engl J Med,2004,351(19) :1941-1951. 被引量:1
  • 9De Zeeuw D, Remuzzi G, Parving H H, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy :Lessons from RENAAL[J]. Kidney Int, 2004,65 (6) : 2309 2320. 被引量:1
  • 10Yusuf S,Teo KK,Pogue J,et al. Telmisartan ,ramipril,or both in pa- tients at high risk for vascular events[J]. New Engl J Med, 2008,358 (15) :1547 1559. 被引量:1

共引文献5

同被引文献14

引证文献2

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部